Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema

Angie HC Fong,1 Timothy YY Lai1,2 1Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong; 22010 Retina and Macula Centre, Tsimshatsui, Kowloon, Hong Kong Abstract: Neovascular age-related macular degeneration (AMD) and diabe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fong AH, Lai TY
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ranibizumab anti-VEGF therapy age-related macular degeneration diabetic macular edema safety diabetic retinopathy cost-effectiveness. Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/a3c167dd3c694b13b81aa2a8ab32b0ce
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a3c167dd3c694b13b81aa2a8ab32b0ce
record_format	dspace
spelling	oai:doaj.org-article:a3c167dd3c694b13b81aa2a8ab32b0ce2021-12-02T00:10:37ZLong-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema1178-1998https://doaj.org/article/a3c167dd3c694b13b81aa2a8ab32b0ce2013-04-01T00:00:00Zhttps://www.dovepress.com/long-term-effectiveness-of-ranibizumab-for-age-related-macular-degener-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Angie HC Fong,1 Timothy YY Lai1,2 1Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong; 22010 Retina and Macula Centre, Tsimshatsui, Kowloon, Hong Kong Abstract: Neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) are major causes of visual impairment in the elderly population worldwide. With the aging population, the prevalence of neovascular AMD and DME has increased substantially over the recent years. Vascular endothelial growth factor (VEGF) has been implicated as playing an important role in the pathogenesis of both neovascular AMD and DME. Since its introduction in 2006, ranibizumab, a recombinant, humanized, monoclonal antibody fragment against all isoforms of VEGF-A, has revolutionized the treatment of neovascular AMD and DME. The efficacy and safety of ranibizumab in neovascular AMD has been demonstrated in the ANCHOR and MARINA trials. Further studies including the PIER, PrONTO, and SUSTAIN trials have also evaluated the optimal dosing regimen of ranibizumab in neovascular AMD. The CATT and IVAN trials compared the safety and efficacy of ranibizumab with off-label use of bevacizumab. Studies such as SUSTAIN and HORIZON have shown that ranibizumab has a good safety profile and is well tolerated for over 4 years with very few serious ocular and systemic adverse events. For DME, Phase II RESOLVE study and Phase III RISE and RIDE studies have demonstrated superiority of ranibizumab treatment in improving vision over placebo controls. Phase II READ and Phase III RESOLVE and REVEAL studies have shown that ranibizumab is more effective both as monotherapy and in combination with laser compared with laser monotherapy. The 3-year results from the DRCRnet protocol I study found that ranibizumab with deferred laser resulted in better long-term visual outcome compared with ranibizumab with prompt laser. This review summarizes various important clinical trials on the long-term efficacy and safety of ranibizumab in the treatment of neovascular AMD and DME. The pharmacological properties of ranibizumab, its cost effectiveness, and impact on quality of life will also be discussed. Keywords: ranibizumab, anti-VEGF therapy, age-related macular degeneration, diabetic macular edema, safety, diabetic retinopathy, cost-effectivenessFong AHLai TYDove Medical PressarticleRanibizumabanti-VEGF therapyage-related macular degenerationdiabetic macular edemasafetydiabetic retinopathycost-effectiveness.GeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 8, Pp 467-483 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ranibizumab anti-VEGF therapy age-related macular degeneration diabetic macular edema safety diabetic retinopathy cost-effectiveness. Geriatrics RC952-954.6
spellingShingle	Ranibizumab anti-VEGF therapy age-related macular degeneration diabetic macular edema safety diabetic retinopathy cost-effectiveness. Geriatrics RC952-954.6 Fong AH Lai TY Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
description	Angie HC Fong,1 Timothy YY Lai1,2 1Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong; 22010 Retina and Macula Centre, Tsimshatsui, Kowloon, Hong Kong Abstract: Neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) are major causes of visual impairment in the elderly population worldwide. With the aging population, the prevalence of neovascular AMD and DME has increased substantially over the recent years. Vascular endothelial growth factor (VEGF) has been implicated as playing an important role in the pathogenesis of both neovascular AMD and DME. Since its introduction in 2006, ranibizumab, a recombinant, humanized, monoclonal antibody fragment against all isoforms of VEGF-A, has revolutionized the treatment of neovascular AMD and DME. The efficacy and safety of ranibizumab in neovascular AMD has been demonstrated in the ANCHOR and MARINA trials. Further studies including the PIER, PrONTO, and SUSTAIN trials have also evaluated the optimal dosing regimen of ranibizumab in neovascular AMD. The CATT and IVAN trials compared the safety and efficacy of ranibizumab with off-label use of bevacizumab. Studies such as SUSTAIN and HORIZON have shown that ranibizumab has a good safety profile and is well tolerated for over 4 years with very few serious ocular and systemic adverse events. For DME, Phase II RESOLVE study and Phase III RISE and RIDE studies have demonstrated superiority of ranibizumab treatment in improving vision over placebo controls. Phase II READ and Phase III RESOLVE and REVEAL studies have shown that ranibizumab is more effective both as monotherapy and in combination with laser compared with laser monotherapy. The 3-year results from the DRCRnet protocol I study found that ranibizumab with deferred laser resulted in better long-term visual outcome compared with ranibizumab with prompt laser. This review summarizes various important clinical trials on the long-term efficacy and safety of ranibizumab in the treatment of neovascular AMD and DME. The pharmacological properties of ranibizumab, its cost effectiveness, and impact on quality of life will also be discussed. Keywords: ranibizumab, anti-VEGF therapy, age-related macular degeneration, diabetic macular edema, safety, diabetic retinopathy, cost-effectiveness
format	article
author	Fong AH Lai TY
author_facet	Fong AH Lai TY
author_sort	Fong AH
title	Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
title_short	Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
title_full	Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
title_fullStr	Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
title_full_unstemmed	Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
title_sort	long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/a3c167dd3c694b13b81aa2a8ab32b0ce
work_keys_str_mv	AT fongah longtermeffectivenessofranibizumabforagerelatedmaculardegenerationanddiabeticmacularedema AT laity longtermeffectivenessofranibizumabforagerelatedmaculardegenerationanddiabeticmacularedema
_version_	1718403880336752640

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema

Ejemplares similares